Products
Platform
Research
Market
Learn
Compare ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund vs UTI Healthcare Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 5.0 | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.87 | 2.25 |
NAV | ₹40.33 | ₹292.75 |
Fund Started | 25 Jun 2018 | 01 Aug 2005 |
Fund Size | ₹6226.82 Cr | ₹1096.95 Cr |
Exit Load | Exit load of 1% if redeemed within 15 days. | Exit load of 1% if redeemed within 30 days. |
Risk
Very High
Very High
Rating
5.0
4.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.87
2.25
NAV
₹40.33
₹292.75
Fund Started
25 Jun 2018
01 Aug 2005
Fund Size
₹6226.82 Cr
₹1096.95 Cr
Exit Load
Exit load of 1% if redeemed within 15 days.
Exit load of 1% if redeemed within 30 days.
Returns
1 Year | 2.62% | 0.80% |
3 Year | 28.00% | 24.88% |
5 Year | 20.28% | 17.55% |
1 Year
2.62%
0.80%
3 Year
28.00%
24.88%
5 Year
20.28%
17.55%
Holding Analysis
Equity | 97.55% | 98.98% |
Cash | 2.45% | 1.02% |
Equity
97.55%
98.98%
Cash
2.45%
1.02%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.58% |
Dr. Reddy's Laboratories Ltd. | 9.10% |
Divi's Laboratories Ltd. | 8.75% |
Aurobindo Pharma Ltd. | 8.25% |
Cipla Ltd. | 6.92% |
Lupin Ltd. | 5.43% |
Alkem Laboratories Ltd. | 4.05% |
Biocon Ltd. | 3.11% |
Gland Pharma Ltd. | 2.97% |
Mankind Pharma Ltd. | 2.95% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.61% |
Ajanta Pharma Ltd. | 5.48% |
Cipla Ltd. | 5.48% |
Lupin Ltd. | 4.70% |
Procter & Gamble Health Ltd. | 3.99% |
Glenmark Pharmaceuticals Ltd. | 3.74% |
Dr. Reddy's Laboratories Ltd. | 3.74% |
Gland Pharma Ltd. | 3.62% |
Apollo Hospitals Enterprise Ltd. | 3.58% |
Alkem Laboratories Ltd. | 3.56% |
Fund Manager
Name | Dharmesh Kakkad | Kamal Gada |
Start Date | 23 Feb 2021 | 02 May 2022 |
Name
Dharmesh Kakkad
Kamal Gada
Start Date
23 Feb 2021
02 May 2022
About Fund
Description | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. |
Launch Date | 25 Jun 2018 | 01 Aug 2005 |
Description
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Launch Date
25 Jun 2018
01 Aug 2005